Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: J Neurochem. 2015 Jun 18;135(6):1203–1217. doi: 10.1111/jnc.13169

Figure 1. Liraglutide treatment promotes cell proliferation in neuroblastoma cells in a dose-dependent manner via CREB phosphorylation.

Figure 1

(A) Liraglutide administration (50 nM) stimulated early (1 h) induction (3.7-fold, P<0.05) of CREB phosphorylation in SH-SY5Y neuroblastoma cells. (B) Liraglutide treatment dose-dependently increased cell viabilities in SH-SY5Y neuroblastoma cells. SH-SY5Y cells were treated with different concentrations (0, 10−7, 10−6 or 10−5M) of liraglutide for 24h. Cell viabilities were subsequently assessed by MTS assay. (C) Liraglutide treatment further increased cell viabilities in GLP-1R-overexpressing SH-SY5Y#9 neuroblastoma cells. SH-SY5Y#9 cells were treated with different concentrations (0, 10−9, 10−8, 10−7, 10−6 M) of liraglutide for 24h. Cell viabilities were subsequently assessed by MTS assay (*P < 0.05; **P <0.01; ***P < 0.001).